281
Participants
Start Date
July 28, 2020
Primary Completion Date
December 27, 2021
Study Completion Date
November 8, 2022
Olpasiran
Dose 1 Dose 2 Dose 3 Dose 4
Placebo
Dose 5
Thjonustumidstod Rannsoknaverkefna, Kopavogur
Royal Prince Alfred Hospital, Camperdown
Herlev Gentofte Hospital, Herlev
Monash Medical Centre, Clayton
Core Research Group Pty Ltd, Milton
Dr Heart Pty Ltd, Woolloongabba
Linear Clinical Research Limited, Nedlands
Aarhus Universitetshospital, Aarhus N
Regionshospitalet Viborg, Viborg
New York University, New York
Mount Sinai Hospital, New York
Columbia University Medical Center, New York
Johns Hopkins, Baltimore
Crossroads Clinical Research Inc, Mooresville
Piedmont Healthcare, Atlanta
Excel Medical Clinical Trials, Boca Raton
Cleveland Clinic, Cleveland
University of Kansas Medical Center, Kansas City
Protenium Clinical Research, Hurst
Baylor College of Medicine, Houston
Westside Medical Associates of Los Angeles, Beverly Hills
LMC Clinical Research Incorporated, Brampton
LMC Clinical Research Incorporated Thornhill, Concord
Ecogene-21, Chicoutimi
Research Institute of McGill University Health Center - Glen Site, Montreal
Clinique des Maladies Lipidiques de Quebec Incorporated, Québec
Asahi General Hospital, Asahi-shi
The Jikei University Kashiwa Hospital, Kashiwa-shi
Asahikawa City Hospital, Asahikawa-shi
Kanazawa Medical University Hospital, Kahoku-gun
Saitama Medical University Hospital, Iruma-gun
Academisch Medisch Centrum, Amsterdam
Rijnstate Ziekenhuis, Arnhem
Haga Ziekenhuis, The Hague
Universitair Medisch Centrum Utrecht, Utrecht
VieCuri Medisch Centrum, Venlo
Lead Sponsor
Amgen
INDUSTRY